Published Date: 13 Mar 2023
Electrophysiologist John Mandrola, MD. and Rachel Lampert, MD, reviewed the LIVE-HCM study comparing exercise and no exercise in people with hypertrophic cardiomyopathy.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
2.
Check for eating disorders in bipolar disorder patients.
3.
tobacco use, the severity of their symptoms, and their desire to give up smoking among cancer survivors.
4.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
5.
Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
Unpacking the Importance of White Blood Cells (WBCs) in the Body
3.
Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response
4.
Understanding Pomalidomide: A promising drug for multiple myeloma treatment
5.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
4.
Navigating the Complexities of Ph Negative ALL - Part XIII
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation